Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
P/B ratio for Chinook Therapeutics, Inc. (KDNY)
P/B ratio as of 2022: 3.82
According to Chinook Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.82. At the end of 2021 the company had a P/B ratio of 1.64.
P/B ratio history for Chinook Therapeutics, Inc. from 2015 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 3.82 |
| 2021 | 1.64 |
| 2020 | 0.62 |
| 2019 | -6.05 |
| 2018 | 7688.39 |
| 2017 | 11512.03 |
| 2016 | 16356.15 |
| 2015 | 24043.04 |